PMID- 36682577
OWN - NLM
STAT- MEDLINE
DCOM- 20230226
LR  - 20230317
IS  - 1096-1194 (Electronic)
IS  - 0890-8508 (Linking)
VI  - 67
DP  - 2023 Feb
TI  - Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in 
      laryngeal squamous cell carcinoma.
PG  - 101895
LID - S0890-8508(23)00004-X [pii]
LID - 10.1016/j.mcp.2023.101895 [doi]
AB  - BACKGROUND: Circulating cell-free DNA (cfDNA) and vascular endothelial growth 
      factor-C (VEGF-C) can be utilized to detect cancer and predict its prognosis. 
      However, their potential application in laryngeal squamous cell carcinoma (LSCC) 
      is unclear. PURPOSE: This study aimed to identify the diagnostic and prognostic 
      value of cfDNA and VEGF-C in LSCC patients. METHODS: The plasma cfDNA of 148 LSCC 
      patients and 43 non-tumor patients were isolated. Quantitative real-time PCR 
      (qRT-PCR) was performed to assess long and short DNA fragments in plasma by 
      amplifying the ALU repeats. ALU-qPCR results (ALU247/ALU115) were used to 
      calculate cfDNA integrity index. Vascular endothelial growth factor-C (VEGF-C) 
      level was detected by ELISA assay. Correlation between cfDNA and clinical 
      features was analyzed. For detecting the sensitivity and specificity of cfDNA and 
      VEGF-C alone or in combination for diagnosing LSCC, receiver operator 
      characteristic (ROC) was established. For evaluating the overall survival (OS) of 
      LSCC, Kaplan-Meier curves were established. RESULTS: LSCC patients had 
      significantly higher levels of plasma cfDNA (ALU115, ALU247, and cfDNA integrity 
      index) and VEGF-C than those without cancer (p < 0.05), showing area under the 
      curve (AUC) values of 0.79, 0.74, 0.62 and 0.80, when cutoff value was 
      correspondingly defined at 2.14 ng/mL, 1.39 ng/mL, 0.73 and 412.90 pg/mL, 
      respectively. The AUC for distinguishing LSCC patients from non-tumor patients by 
      plasma cfDNA combined with VEGF-C was 0.89 (95% CI: 0.83-0.94). A significant 
      correlation was found between plasma cfDNA levels and Ki-67, tumor size, pT 
      stage, and smoking history (p < 0.05). Based on survival analysis, low VEGF-C 
      concentration groups had longer OS than those with high VEGF-C concentration 
      (p = 0.02). CONCLUSION: Indicators such as plasma cfDNA and VEGF-C may be used to 
      diagnose and monitor LSCC for its noninvasiveness and rapid accessibility.
CI  - Copyright (c) 2023. Published by Elsevier Ltd.
FAU - Huang, Qiang
AU  - Huang Q
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, 200031, China.
FAU - Ji, Mengyou
AU  - Ji M
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, 200031, China.
FAU - Li, Feiran
AU  - Li F
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, 200031, China.
FAU - Li, Yufeng
AU  - Li Y
AD  - Department of Anesthesiology, Eye & ENT Hospital, Fudan University, Shanghai, 
      200031, China.
FAU - Zhou, Xuehua
AU  - Zhou X
AD  - Department of Anesthesiology, Eye & ENT Hospital, Fudan University, Shanghai, 
      200031, China.
FAU - Hsueh, Chi-Yao
AU  - Hsueh CY
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, 200031, China. Electronic address: hsuehchiyao@gmail.com.
FAU - Zhou, Liang
AU  - Zhou L
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, 200031, China. Electronic address: zhoulent@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230119
PL  - England
TA  - Mol Cell Probes
JT  - Molecular and cellular probes
JID - 8709751
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cell-Free Nucleic Acids)
RN  - 0 (Vascular Endothelial Growth Factor C)
RN  - 0 (VEGFC protein, human)
SB  - IM
MH  - Humans
MH  - Biomarkers, Tumor/genetics
MH  - *Cell-Free Nucleic Acids
MH  - *Head and Neck Neoplasms
MH  - Prognosis
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Vascular Endothelial Growth Factor C
OTO - NOTNLM
OT  - Cell-free DNA
OT  - Diagnostic
OT  - Laryngeal squamous cell carcinoma
OT  - Prognostic
OT  - VEGF-C
COIS- Declaration of competing interest The authors have no relevant financial or 
      non-financial interests to disclose.
EDAT- 2023/01/23 06:00
MHDA- 2023/02/25 06:00
CRDT- 2023/01/22 19:26
PHST- 2022/09/12 00:00 [received]
PHST- 2023/01/18 00:00 [revised]
PHST- 2023/01/18 00:00 [accepted]
PHST- 2023/01/23 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2023/01/22 19:26 [entrez]
AID - S0890-8508(23)00004-X [pii]
AID - 10.1016/j.mcp.2023.101895 [doi]
PST - ppublish
SO  - Mol Cell Probes. 2023 Feb;67:101895. doi: 10.1016/j.mcp.2023.101895. Epub 2023 
      Jan 19.